Last deal
Amount
Stage
Date
all rounds
Total amount
date founded
Financing round
General
About Company
Industry
Sector :
Subsector :
founded date
founders
Number of employees
Company Type
Last funding type
IPO status
Contacts
Similar Companies1000
Merz Pharma
Merz Pharmaceuticals specialises in the research and marketing of drugs for the treatment of neurological and psychiatric diseases.
Sector
Subsector
Keywords
Location
AOP Orphan Pharmaceuticals
AOP Orphan Pharmaceuticals develops, markets, and distributes medicines for orphan indications and complex diseases.
Sector
Subsector
Keywords
Location
4B Technologies
4B Technologies develops pharmaceutical treatments for nerve pain symptoms.
Sector
Subsector
Keywords
Location
total rounds
total raised
Eisai Europe
Eisai Europe is a pharmaceutical company that develops small molecule drugs to treat neurodegenerative conditions and solid tumors.
Sector
Subsector
Keywords
Location
M&A Details1
Transaction name
Acquired by
Teva Pharmaceutical Industries
announced date
price
Financials
Funding Rounds7
Number of Funding Rounds
Money Raised
Their latest funding was raised on 28.11.2012. Their latest investor Safeguard Scientifics. Their latest round Post-IPO Debt
Co-Investors
Investors8
Number of lead investors
Number of investors
Safeguard Scientifics
Safeguard Scientifics provides capital and operational support to growth-stage health care and technology companies.
Sector
Subsector
Keywords
Location
total rounds
total raised
count Of Investments
count Of Exists
Gary Kurtzman
Gary Kurtzman has more than 25 years of experience as an entrepreneur, board member, financier and operator. As Managing Director of Healthcare at Safeguard Scientifics (NYSE:SFE), Gary Kurtzman leverages his medical expertise to empower businesses to enhance their products, expand their services, and identify strategic partnership opportunities. Gary Kurtzman has realized value for companies through a series of successful IPOs, M&A and turnaround transactions—most recently Shire’s acquisition of Safeguard’s partner company Advanced BioHealing for $750 million, in cash; and Eli Lilly’s acquisition of Safeguard’s partner company Avid Radiopharmaceuticals for $300 million, up front, with an additional $500 million payout dependent upon the achievement of future regulatory and commercial milestones. Gary Kurtzman’s previous experiences include leadership roles at BioAdvance, Pluvita Corporation, Genovo, Avigen, and Gilead Sciences. Presently, Gary Kurtzman is a lecturer in the Health Care Systems Department at the Wharton School at the University of Pennsylvania where he teaches entrepreneurship in life sciences. In addition, he is also a member of the board at Safeguard’s partner companies Alverix, Crescendo Bioscience, Good Start Genetics, Medivo and PixelOptics.
current job
BioAdvance
BioAdvance is a Pennsylvania-based venture capital firm that funds life sciences startups.
Sector
Subsector
Keywords
Location
total rounds
total raised
count Of Investments
count Of Exists
Battelle Ventures
Battelle Ventures is a venture capital firm that invests in early-stage technology companies with innovative solutions to market problems.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
People
Founders1
Employee Profiles10
Mark W. Pierce
Vice President and Chief Scientific Officer
Jerry McLaughlin
Senior Vice President and Chief Commercial Officer